MedTrace Logo

A Study in Healthy People to Test How Itraconazole Influences the Amount of BI 3031185 in the Blood

NCT07211425 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-02-04

No results posted yet for this study

Summary

The main objective of this trial is to investigate the effect of multiple oral doses of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics of a single dose of BI 3031185 following oral administration.

Conditions

  • Healthy

Interventions

DRUG

BI 3031185

BI 3031185

DRUG

Itraconazole

Itraconazole

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-08
Primary Completion
2026-01-21
Completion
2026-01-21
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07211425 on ClinicalTrials.gov